These authors contributed equally to this manuscript and are co–first authors.
HOW DO I . . . ?
How we approach an acquired thrombotic thrombocytopenic purpura patient
Article first published online: 29 JUL 2014
© 2014 AABB
Volume 54, Issue 10, pages 2375–2382, October 2014
How to Cite
Raval, J. S., Mazepa, M. A., Brecher, M. E. and Park, Y. A. (2014), How we approach an acquired thrombotic thrombocytopenic purpura patient. Transfusion, 54: 2375–2382. doi: 10.1111/trf.12794
- Issue published online: 10 OCT 2014
- Article first published online: 29 JUL 2014
- Manuscript Accepted: 2 JUN 2014
- Manuscript Revised: 15 MAY 2014
- Manuscript Received: 19 FEB 2014
Acquired thrombotic thrombocytopenic purpura (TTP) is a disease characterized by microangiopathic hemolytic anemia and thrombocytopenia, in addition to variable fever and neurologic and renal dysfunction, without an underlying cause. Recent advances in elucidating the pathophysiology of acquired TTP have led to new testing that we have incorporated into our current management of patients with suspected acquired TTP. Despite these developments, much of the treatment for acquired TTP beyond therapeutic plasma exchange (TPE) is based on low-quality evidence. Our group has a sustained interest in studying and optimizing the use of TPE, along with other concurrent therapies, in acquired TTP patients. Described herein is a summary of how our apheresis consult service approaches requests for TPE in patients with suspected acquired TTP.